Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 t-haNK, N-803, and Rituximab in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07125872Phase 2Recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Nov 2025
- Primary completion
- May 2027
- Modality
- Gene Editing, Gene Silencing, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of CD19t-haNK, nogapendekin alfa inbakicept in B-cell non-Hodgkin lymphoma, sponsored by ImmunityBio, Inc.. Started Nov 2025; status: recruiting.
02
Drugs
CD19t-haNKnogapendekin alfa inbakicept
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07125872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07125872.